Login
$ADPT
$26.27 +$0.76 (2.98%) Close

Company Executives

$ADPT Management Team

Mr. Chad Robins

Chairman of the Board

Chief Executive Officer

Co-Founder

Age 50
Compensation $4.973M USD
Sex Male

Ms. Julie Rubinstein

President

Chief Operating Officer

Age 53
Compensation $2.645M USD
Sex Female

Ms. Karina Calzadilla

Vice President - Investor Relations

Age -
Compensation -
Sex Female

Dr. Harlan Robins

Co-Founder

Chief Scientific Officer

Age 52
Compensation $4.540M USD
Sex Male

Mr. Kyle Piskel

Chief Financial Officer

Age 41
Compensation $1.290M USD
Sex Male

Mr. Francis Lo

Chief People Officer

Age 44
Compensation -
Sex Male

Dr. Sharon Benzeno

Chief Commercial Officer - Immune Medicine

Age 51
Compensation $1.797M USD
Sex Female

Ms. Susan Bobulsky

Chief Commercial Officer - MRD

Age 44
Compensation -
Sex Female
Directors
5
serving now
Independent
4 of 4
stated in the proxy; 1 not stated
Average tenure
9.5 years
from year joined
CEO also chairs the board
Not stated
no chair stated
Director Age On board Independent Committees Other public boards 2025 pay Source
Robert Hershberg
Not stated 2013
13 years
Independent
Compensation and Human Capital Committee · Chair Nominating and Corporate Governance Committee
Hillevax, Inc., Recursion Pharmaceuticals, Inc. $324,997
Katey Owen
Not stated 2021
5 years
Independent
Audit Committee Compensation and Human Capital Committee
None stated $309,997
Michelle Griffin
Not stated 2019
7 years
Independent None stated None stated $329,997
Peter Neupert
Not stated 2013
13 years
Independent
Nominating and Corporate Governance Committee · Chair
Laboratory Corporation of America Holdings $354,997
Chad Robins
Not stated Not stated Not stated None stated None stated Paid as CEO

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

7 disclosed in the proxy filed Apr 24, 2026
Viking Global Entities
beneficially owns more than 5% of our common stock
Amount not stated
May 30, 2019

Seventh amended and restated investors rights agreement providing registration, information, first offer and first refusal rights; most rights terminated at IPO.

With certain purchasers of our capital stock Open in proxy
$35,725 each
March 2021

Purchased 250,000 shares of DigitalBio common stock (2.5% interest) in March 2021.

With Digital Biotechnologies, Inc. Open in proxy
Harlan Robins, PhD
$35,725 each
March 2021

Purchased 250,000 shares of DigitalBio common stock (2.5% interest) in March 2021.

With Digital Biotechnologies, Inc. Open in proxy
Julie Rubinstein
$71,450
March 2021

Purchased 500,000 shares of DigitalBio common stock (5% interest) in March 2021.

With Digital Biotechnologies, Inc. Open in proxy
family trusts related to Mr. and Dr. Robins
trusts related to Mr. Robins and Dr. Robins
$285,800
March 2021

Purchased an aggregate of 2,000,000 shares of DigitalBio common stock (20% interest) in March 2021.

With Digital Biotechnologies, Inc. Open in proxy
Julie Rubinstein and family trusts related to Mr. Robins, Dr. Robins and Ms. Rubinstein
Amount not stated
December 2025 through February 2026

Participated in DigitalBio Series A Preferred Stock financing, purchasing an aggregate of 557,142 shares (about 4% of DigitalBio).

With Digital Biotechnologies, Inc. Open in proxy
directors and certain executive officers
directors and certain executive officers of the company
Amount not stated

Indemnification agreements requiring the company to indemnify directors and certain executive officers for expenses, judgments, fines and settlements.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support